Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNO versus intravenous sildenafil for pulmonary hypertension in newborns with congenital diaphragmatic hernia
NL-OMON50767Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Apr 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pulmonary hypertension (PH) and congenital diaphragmatic hernia (CDH) comparing Inhaled nitric oxide with Intravenous sildenafil (2 arms). Primary endpoint: Change in oxygenation index after 12 hours of treatment. Started Apr 2018; status: completed.
02
Drugs
nitric oxidesildenafil
03
Conditions
pulmonary hypertension (PH)congenital diaphragmatic hernia (CDH)
Beyond the preview
Go deeper on NL-OMON50767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50767.